GlassScriptPhysician profile
Gary G Morasca
NPI 1245341767
$8,200.39
in general payments reported to CMS, 2019-2025
35 companies · $1,614 in 2025
The $1,614 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $381 · 2021: $498 · 2022: $1,362 · 2023: $1,951 · 2024: $1,992 · 2025: $1,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,556.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,301.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,013.89 | 2020-2025 | |
| Glaxosmithkline, LLC. | $969.09 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $773.99 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $743.40 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $664.24 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Supernus Pharmaceuticals, INC. | $355.56 | 2019-2021 | |
| Pfizer INC. | $351.72 | 2021-2025 | |
| Astellas Pharma US INC | $323.22 | 2019-2025 | Veozah |
| Daiichi Sankyo INC. | $266.20 | 2022-2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $233.16 | 2023-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $158.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.03 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Nevro Corp. | $102.88 | 2023-2024 | Senza |
| Merck Sharp & Dohme LLC | $101.81 | 2019-2023 | Verquvo, Belsomra, Steglatro |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $80.82 | 2022-2023 | Quviviq |
| Abbott Laboratories | $78.76 | 2023-2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $72.81 | 2024-2025 | Voquezna |
| Phadia US INC. | $71.93 | 2022 | |
| Exact Sciences Corporation | $49.16 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $48.28 | 2019-2020 | |
| Dexcom, INC. | $47.48 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $45.11 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $44.94 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $32.89 | 2020-2024 | Uzedy |
| Scilex Pharmaceuticals INC. | $17.61 | 2023 | Ztlido |
| Otsuka America Pharmaceutical, INC. | $17.48 | 2023 | Rexulti |
| Sanofi Pasteur INC. | $17.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.54 | 2022 | |
| Shield Therapeutics INC | $16.45 | 2024 | |
| Currax Pharmaceuticals LLC | $14.67 | 2024 | Contrave |
| Therapeuticsmd, INC. | $12.64 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $12.57 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.22 | 2020 | |
| Organon LLC | $2.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Morasca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.